Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471197 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01471197 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 9 participants.
The verdict
NCT01471197, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
Interventions
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471197
The ClinicalTrials.gov registry entry for NCT01471197 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01471197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471197 about?
NCT01471197 is a clinical study titled "Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer". The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
What is the current status of trial NCT01471197?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-07. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01471197?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), Pemetrexed (BIOLOGICAL).
Who is sponsoring clinical trial NCT01471197?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.